This trial is looking at how well the body maintains blood flow to the skin during and after exposure to local heat, as well as during administration of drugs that narrow blood vessels.
- Cardiovascular Disease
- Cardiovascular Risk
1 Primary · 0 Secondary · Reporting Duration: Through study completion, an average of 1 Year
4 Treatment Groups
1 of 4
Inhibitor of Endothelin Type B Receptor
1 of 4
1 of 4
Inhibition of Endothelin Type A Receptor
1 of 4
50 Total Participants · 4 Treatment Groups
Primary Treatment: BQ-123 · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 35 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is geriatric participation being accepted in this clinical trial?
"Patients must be aged 18-35 to qualify for this trial. Meanwhile, 49 studies are available to participants below the age of majority and 512 trials catered towards seniors above 65 years old exist." - Anonymous Online Contributor
For whom is enrollment into this clinical study available?
"For admittance in this trial, participants must be between 18-35 years old and display signs of vasoconstriction. The total number of patients accepted is 50." - Anonymous Online Contributor
What precedent exists for the application of BQ-123 in clinical settings?
"Currently, BQ-123 is the subject of 126 active medical trials. Of these tests, 31 are in Phase 3 and most of them originate from Calgary, Alberta. However, its clinical trials can be found at 445 different sites worldwide." - Anonymous Online Contributor
Is enrollment still open for this clinical trial?
"Affirmative. Information displayed on clinicaltrials.gov suggests that this research effort, which was first posted in October 2018 and revised in February 2022, is actively recruiting subjects for participation. Approximately 50 individuals are required from a single location." - Anonymous Online Contributor
What is the total number of participants for this experiment?
"Correct. According to the information on clinicaltrials.gov, this trial is currently enrolling patients with an initial post date of October 1st 2018 and a last update from February 7th 2022. This medical study requires 50 participants across one location." - Anonymous Online Contributor
Does this research break new ground in its field?
"BQ-123 has been a subject of medical research since 2007, when Baxter Healthcare Corporation first sponsored the initial clinical trial with 4640 participants. After the satisfactory results were published in early 2008, BQ-123 received its Phase 4 drug approval and is presently being studied at 126 sites across 187 cities and 37 countries." - Anonymous Online Contributor
What conditions is BQ-123 employed to alleviate?
"BQ-123 is typically used in haemodiafiltration, yet it also has therapeutic potential for increasing intra ocular pressure (iop), alleviating nasal discomfort, and improving renal function." - Anonymous Online Contributor
Has the FDA accepted BQ-123 for general use?
"Our team at Power gave BQ-123 a rating of 1 on the safety scale, as this is an early Phase 1 trial with limited evidence to support its efficacy and security." - Anonymous Online Contributor